­Capabilities: Full industry chain from R&D to independent production and commercialization. Innovative Drug Production: The Baili-Bio Base has established an antibody/ADC drug production workshop in accordance with cGMP standards, capable of meeting the clinical sample production needs of innovative biologics and early commercial production needs after approval. Generic Drug Production: Through the synergistic effect among the Guorui Base (for injectables and oral formulations), Baili Base (for oral solid formulations and lyophilized injectables), and Hyatt/Jingxi Base (for intermediates and chemical APIs), the company has strategically established a "API-Finished Pharmaceutical" generic drug and traditional Chinese medicine production platform. This production platform integrates the production process from raw materials to finished products, ensuring continuous and sufficient supply for commercial sales of already launched products。